Meanwhile, the selective EIF4A3 inhibitor eIF4A3-IN-2 decreased osteoblastogenesis and inhibited the bone metastasis induced by breast cancer cells (Xu et al., 2021). This evidence concerns the gene CD44 and breast carcinoma.